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Summary Total y-glutamyl transferase and alkaline phosphatase, liver-specific alkaline phosphatase and high
molecular weight forms of the two enzymes were measured in the sera of 42 patients with colorectal cancer, of
whom 26 were apparently metastases-free and 16 had palpable liver metastases. The average levels of all
enzymes were significantly higher in the group with metastases, but there was considerable overlap between
the groups. The predictive values of positive results were of the order of 50-75%; predictive values of
negative results were more than 70% for all tests, with high molecular weight alkaline phosphatase (87%)
performing best in this respect. However, measurement of high molecular weight enzymes does not offer
marked advantages over more conventional enzyme tests in the detection of hepatic metastases of colorectal
cancer.
The place of measurements of enzyme activities in
serum as a non-invasive method of pre-operative
screening for hepatic metastases in patients with
colorectal and other cancers has been the subject of
numerous reports (Beck et al., 1979, Tartter et al.,
1981; Cooper et al., 1975; Kemeny et al., 1982).
Alkaline phosphatase (EC 3.1.3.1; ALP) and
y-glutamyl transferase (EC. 2.3.2.2; GGT) are
generally considered to be the most sensitive tests in
current use (Huguier and Lacaine, 1981; Read et
al., 1977; Aronsen et al., 1970). However, many
patients with hepatic metastases have normal levels
of these enzymes while some patients without
detectable metastases have elevated levels.
In a high proportion of patients with elevated
serum ALP due to cholestatic liver disease a high
molecular weight form of ALP is present, and this
form of ALP has been reported to be almost
invariably present in sera from patients with
hepatic metastases (Viot et al., 1979; Crofton et al.,
1979). A considerable part of the high molecular
weight ALP fraction (also known as the 'fast liver'
or 'biliary' phosphatase) has been shown to consist
of cell-membrane fragments, with which are
associated other membrane-bound enzyme activities
such as GGT (De Broe et al., 1975). As well as
occurring in serum in the form of membrane
fragments ('koinozymes'), other high molecular
weight fractions of GGT, and possibly also of ALP,
may occur in serum as a result of such processes as
aggregation of enzyme molecules with other
enzymic or non-enzymic substances (Echetebu &
Moss, 1982). It is possible that destructive lesions
of the liver, such as those caused by malignant
infiltration, may promote the disintegration of
cellular membranes, thus causing the reportedly
high incidence of high molecular weight enzyme
fractions in serum.
We now report the results of a study of the
occurrence of high molecular weight ALP and
GGT in sera in patients with colorectal cancer. The
value of these fractions as indicators of hepatic
metastases has been compared with that of
measurements of total ALP and GGT, and with
specific measurement of liver type ALP (L-ALP).
Patients and methods
Forty-two consecutive patients with colorectal
cancer were studied. The 42 patients ranged in age
from 43-81 years (mean age=62 years). There were
19 men and 23 women. Thirty three patients had
primary lesions in the left colon or rectum and 9
patients had primary lesions in the right colon or
caecum. All patients had preoperative serum
estimations of total ALP, liver isoenzyme of ALP
(L-ALP) and high molecular weight ALP (H-ALP),
and total GGT and high molecular weight GGT
(H-GGT). Every patient subsequently underwent
laparotomy within 1 week of blood sampling. At
laparotomy, bimanual palpation of the liver was
performed, care being taken to palpate and examine
the entire liver. Needle biopsy of every suspicious
lesion was performed. Liver metastases were
detected by bimanual palpation of the liver in 16
patients (38%).
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Measurements of the high molecular weight
enzymes were also carried out on sera from 16
normal subjects with a similar age-range to that of
the patients.
Enzyme measurements were performed at 37°C
on a LKB Produkter AB 8600 reaction rate
analyzer. The methods used for measurement of
total ALP and total GGT were those recommended
by the Committee on Enzymes of the Scandinavian
Society for Clinical Chemistry and Clinical
Physiology (1971, 1976 respectively). H-ALP and
H-GGTactivitiesweremeasuredbythesamemethods
after separation by gel filtration (Figure 1) on a
Sepharose 6B column (Pharmacia, Uppsala,
Sweden) of sera stored at 4°C for less than 5
days. Liver alkaline phosphatase was measured by
the progressive heat-inactivation procedure of Moss
& Whitby (1975). The precision of the enzyme
assays was within 8% (c.v.) at normal levels and
within 5% (c.v.) at elevated levels.
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values. Upper reference values for H-ALP and
H-GGT were derived from data obtained for normal
subjects, since these have not been established
previously.
All results were analyzed statistically and the
significance of differences between patients with
metastases and patients without metastases was
verified by the Mann-Whitney test for non-
parametric data.
Results
Total ALP was elevated in 9 of 16 patients with
liver metastases and 3 of 26 patients without
metastases. Although the means of the groups were
significantly different (P<0.003), the results for the
two groups overlapped considerably (Figure 2).
Liver ALP was elevated in the same 9 patients with
metastases and also in 5 without metastases. Again,
although the difference between means was highly
significant (P<0.002), the groups overlapped
extensively (Figure 2).
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Figure 1 Examples of gel-filtration profiles, showing
presence of high molecular weight alkaline
phosphatase (H-ALP; solid line) and high molecular
weight y-glutamyltransferase (H-GGT; broken line) in
(a) normal serum, and sera from patients (b) without
and (c) with metastases. High molecular weight
fractions are those eluting to the left of the arrows.
The upper reference values for total ALP and
L-ALP vary according to age (Whitaker et al., 1977)
and the upper reference values for GGT vary
according to sex (Rosalki, 1975). For this reason,
results are presented graphically as multiples of the
upper reference value rather than as absolute
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Figure 2 Total ALP, liver-specific ALP (L-ALP) and
total GGT in sera of patients with colorectal cancer,
with ('Mets') and without ('No mets') palpable hepatic
metastases.
Total GGT showed a similar pattern. Levels were
abnormal in 9 of 16 patients with metastases and in
7 of 26 patients without metastases, with a
significant difference in means (P=0.005) but with
extensive overlap (Figure 2).
Both high molecular weight ALP and high
molecular weight GGT were detectable in the sera
of normal subjects after gel filtration. The range of
values was from 3.5 to 11.2UP-1 for H-ALP, and
0.7 to 4.5 UI- for H-GGT. The data for both of
these tests were found to fit well to log-normal
distributions, and upper (97.5%) reference values
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calculated accordingly were 12 U - for H-ALP
and 6UI1- for H-GGT. These values were used to
interpret the activities of these components in sera
from the patients.
H-ALP was significantly greater (P=0.002) in
the patients with metastases than in those without.
However, individual values again overlapped
(Figure 3). Fourteen of 16 cancer patients with
metastases and 13 of 26 without metastases had
elevated levels. Results for H-GGT were rather
similar, with values of H-GGT being significantly
greater in the group with metastases than in the
group without metastases (P<0.008). Values in the
two groups of patients overlapped (Figure 3).
Eleven of 16 cancer patients with metastases had
elevated levels, as had 10 of 26 without metastases.
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Figure 3 Levels of H-ALP and H-GGT in sera of
patients with colorectal cancer, with ('Mets') and
without ('No mets') palpable hepatic metastases.
Broken lines indicate upper reference values.
No improvement in discrimination between
groups of patients with and without metastases was
obtained by expressing H-ALP or H-GGT as
percentages of the respective total enzyme activities.
Similarly, discriminant function analysis involving 2
or more enzyme tests did not improve
discrimination between the groups.
Discussion
Pre-operative detection of hepatic metastases in
patients with colorectal cancer allows important
planning decisions to be made regarding additional
procedures which may be required, e.g. hepatic
resection (Fortner et al., 1984a; Adson & Van
Heerden, 1980) or placement of catheters for intra-
or post-operative perfusion chemotherapy (Fortner
et al., 1984b; Ansfield & Ramirez, 1978). The most
reliable pre-operative test for hepatic metastases
currently available is computer-assisted tomography
with detection rates of 85-95% (Snow et al., 1979;
Smith et al., 1982) compared with 65-85% for
ultrasound scans, isotope scans and angiography
(Knopf et al., 1982; Bondestam et al., 1980; Kim et
al., 1975). However, the last two procedures are
complex and invasive, so that a useful role exists
for a simple non-invasive biochemical screening test
which would alert the clinician to the need for
further diagnostic tests.
The value of serum enzyme measurements in
screening for hepatic metastases has been limited by
the poor sensitivity and specificity of many of the
enzymes measured in the past, e.g., aspartate and
alanine aminotransferases, lactate dehydrogenase
(Castagna et al., 1972; Schaefer & Schiff, 1965).
ALP and GGT have consistently demonstrated
superior sensitivity to these enzymes, but ALP may
be elevated due to bone disease, and both ALP and
GGT may be elevated in hepatic diseases other
than metastases. The specificity and sensitivity of
ALP as an indicator of liver involvement can be
improved by measuring the liver-derived form of
the enzyme (L-ALP). GGT is highly specific for
hepatobiliary disease, but neither GGT nor L-ALP
can distinguish between malignant infiltration and
other liver diseases. The hypothesis that H-ALP
and H-GGT may have some degree of specificity
for liver metastases, because of the destructive
nature of the lesions, is therefore worth
investigation.
The present results do not demonstrate any
marked advantage of H-GGT or H-ALP over other
enzyme tests in the detection of hepatic metastases
(Table I). Their efficiencies (sum of true positive
and true negative results as a percentage of all
patients) are rather lower than those of the other
tests. This derives from the higher proportion of
false positives (raised levels in patients without
metastases) given by H-GGT and H-ALP; for the
same reason, the predictive value of a positive
Table I Efficiencies and predictive values of positive and
negative results of various enzyme tests in the detection of
hepatic metastases ofcolorectal cancer
Predictive value of
Positive Negative
Test Efficiency result result
Total ALP 76 75 77
Total GGT 67 56 73
L-ALP 71 64 75
H-ALP 64 52 87
H-GGT 67 55 77
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result is lower for H-GGT and H-ALP than the
other tests.
The predictive value of a negative result is similar
for all the tests other than H-ALP, which performs
rather better in this respect than other tests.
However, these assessments depend markedly on
the levels chosen to discriminate between normal
and abnormal results, and the reference limits for
H-ALP and H-GGT are based on fewer data than
those for the other tests. A similar incidence of
false positive H-ALP values (20%) in patients
without liver metastases, with a high incidence
(79%) of abnormal values in patients with
metastases, has been reported in a study of patients
with breast cancer (Karmen et al., 1984).
The similarity between results for total GGT and
H-GGT, and L-ALP and H-ALP, may indicate
that the processes which lead to the release of these
enzymes from liver cells may be similar in the
absence and presence of palpable metastases; i.e.
destruction of hepatocytes by invading tumour
cells may not be necessary for membrane fragments
to be released. An important factor in shedding of
membrane fragments due to metastases may be
local cholestasis (e.g., leading to elution of
membrane components through detergent action).
Local cholestasis may occur even before discrete
metastases are palpable, and this may account for
the high proportion of positive results by all tests in
patients in whom no metastases could be felt. In
the 20 patients without palpable liver metastases in
whom follow-up was possible, 14 remained free of
metastases over periods of up to 36 months (mean
22 months) and 3 had local recurrence without
metastases, while 3 developed liver metastases after
intervals of 4, 15 and 13 months. Of the last three
patients, the first 2 had markedly elevated levels of
H-GGT and H-ALP when first examined; whether
high levels of these enzyme forms suggest an
increased risk of hepatic involvement therefore
seems to merit further investigation.
The low levels of H-ALP and H-GGT present in
normal sera were not correlated (r=0.06)
suggesting that, in these samples, different
aggregates of the two enzymes are present.
However, in patients (with or without palpable liver
metastases) the levels were strongly correlated
(r=0.89), as would be expected as a result of the
release of cell membrane fragments carrying both
ALP and GGT. It is not possible at present to
determine whether the specific activities of the
complexed enzymes are reduced compared with
those of lower molecular weight forms, and
therefore whether activity measurements under-
estimate the relative amounts ofcomplexed enzymes
present in serum.
The work presented in this paper was partly supported by
the Cancer Research Campaign.
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